Amgen Inc. (AMGN) Piper Sandler Digital Novel Targets in Immunology Symposium February 12, 2026 5:00 PM EST
Firm Contributors
Paul Burton – Senior VP & Chief Medical Officer
Casey Capparelli – Govt Director of Investor Relations
Convention Name Contributors
David Amsellem – Piper Sandler & Co., Analysis Division
Presentation
David Amsellem
Piper Sandler & Co., Analysis Division
All proper, everybody. Good afternoon. That is David Amsellem from the Piper Sandler Biopharma Analysis workforce and a contented virtually Friday to everybody listening in. So within the subsequent 25 minutes, we will be talking with Amgen and plenty to speak about on the subject of immunology and irritation. We’re delighted to have CMO, Paul Burton. We even have from the IR workforce or the Head of the IR workforce Casey Capparelli as nicely. Thanks, gents, for becoming a member of us.
Query-and-Reply Session
David Amsellem
Piper Sandler & Co., Analysis Division
So I do know there’s quite a bit to speak about. And final week, there have been some new developments when it comes to new scientific trial initiations and likewise new information. So I am admittedly going to bounce round. However one product I needed to begin with, Paul, in case you do not thoughts, is UPLIZNA. So clearly, you had the label expansions final yr. However you probably did talk about final week plans to provoke Section III research in autoimmune hepatitis and likewise power inflammatory demyelinating polyneuropathy later this yr. So I assume a high-level query right here. You bought a B-cell depleter in UPLIZNA. So perhaps discuss your rationale right here for shifting forward with these 2 scientific settings and assist us higher perceive the rationale for B-cell depletion in each of those scientific settings.
Paul Burton
Senior VP & Chief Medical Officer
Nice. David, look, thanks for having us. I feel as an organization, we have now robust expertise in B-cell depletion. We have now BLINCYTO which